In-Depth Notes on Therapeutic Drug Monitoring

Overview

• Speaker Information: Dr. Benjamin Jung, PhD, Clinical Biochemist at SickKids, University of Toronto, is a recognized expert in the field of clinical biochemistry and therapeutic drug monitoring (TDM), bringing extensive experience in optimizing drug therapies in pediatric populations.

• Lecture Date: March 27, 2025, during which Dr. Jung presented current advancements and methodologies in TDM.

• Key Contribution: Slides by Dr. Lei Fu, encapsulating the latest research findings and practical scenarios in the application of TDM.

Learning Objectives

• Define TDM: Understanding its role in optimizing drug therapy, enhancing patient outcomes while minimizing adverse effects.

• Explain Pharmacokinetics & Pharmacodynamics: The importance of these principles in the context of TDM for understanding drug behavior in the body and their effects.

• Identify Influential Factors: Patient-specific variables, including age, weight, genetics, and concurrent medications, that can significantly affect drug levels and efficacy.

• Indications for TDM: Detailed understanding of the contexts when TDM is crucial for successful therapy management.

• Explore Pharmacogenetics: Examination of how genetic variations influence drug metabolism and response, supporting personalized medicine.

What is Therapeutic Drug Monitoring (TDM)?

• Definition: Measurement of drug levels in blood or body fluids to optimize clinical response while minimizing toxicity, ensuring effective therapeutic management.

• Main Concept: Emphasizes the correlation between drug plasma levels and clinical effect, typically illustrated by a Dose Response Curve which indicates:- Higher Concentration = Greater Response, showcasing the importance of achieving therapeutic levels without reaching toxicity.

  • EC50: Concentration at which half of the maximum effect is achieved—crucial for determining effective dose ranges.

Drug Safety – Therapeutic Index

• Assessment: Quantal dose-response curves aid in determining the safety and efficacy of drugs by analyzing individual responses at varying doses.

• Key Terms:

  • ED50: The effective dose at which 50% of patients exhibit a therapeutic effect.

  • TD50: The toxic dose that produces an adverse effect in 50% of subjects.

  • Therapeutic Index: The ratio ( TI = \frac{TD{50}}{ED{50}} ) that quantifies drug safety; a larger therapeutic index reflects a safer therapeutic range, highlighting the importance of diligent monitoring in TDM.

When is TDM Used?

• General Use: While TDM is not routinely performed for most prescribed drugs, it becomes imperative in specific situations to ensure drug safety and efficacy.

• Indications include:

  • Drugs with narrow therapeutic ranges where the margin between therapeutic and toxic doses is minimal.

  • Individual variability in pharmacokinetics due to genetic polymorphisms impacting drug metabolism.

  • Special populations at increased risk of adverse drug reactions: such as pregnant women, neonates, and elderly patients.

  • Compliance assessments in chronic therapy to ensure patients are adhering to their prescribed regimen.

  • Considerations in polypharmacy where multiple medications may affect absorption, distribution, metabolism, or excretion,

Pharmacology

Pharmacokinetics (What the body does to the drug)

• Processes: Involves Absorption, Distribution, Metabolism, Excretion (ADME) that dictate the bioavailability and therapeutic effectiveness of drugs.

• Impact: These processes significantly influence the concentration of drugs in the bloodstream, effectiveness, and potential for toxicity, necessitating careful monitoring.

Pharmacodynamics (What the drug does to the body)

• Focus: Examines the mechanism of action of drugs, molecular interactions at receptor sites, and the overall effects they exert on the physiological functioning of the body.

Factors Affecting Pharmacokinetics

1. Absorption

• Oral Route: Highly dependent on gastrointestinal function, including motility, pH levels, and dietary factors which can significantly affect drug bioavailability.

• Intravenous Route: Achieves 100% bioavailability and is often utilized in acute care settings for rapid drug action.

2. Distribution

• Influenced by factors such as blood perfusion rates and the extent of protein binding which dictate the amount of free drug available to exert therapeutic effects.

• Tissue Permeability: A key factor that affects the drug's access to various body compartments, including critical areas like the Central Nervous System (CNS).

3. Metabolism

• Primarily occurs in the liver involving cytochrome P450 enzymes, which play a crucial role in drug biotransformation.

• Enzyme induction or inhibition can lead to significant fluctuations in drug levels and impacts on pharmacological activity.

4. Excretion

• Mainly mediated through renal functions; however, hepatic excretion through bile also plays a significant role, especially for certain classes of drugs.

Grapefruit Juice Interaction

• Mechanism: Grapefruit juice negatively affects the metabolism of various medications by blocking enzymes and transporters responsible for their absorption and biotransformation,

• It can significantly impact drug effectiveness or safety.- Among the drugs affected are:

  • Statins: Grapefruit inhibits CYP3A, leading to increased serums levels and heightened risk of overdose and adverse effects.

  • Allergy medications (e.g., Allegra/Fexofenadine): Grapefruit inhibits OATP1A2 transporters, reducing the drug's therapeutic effectiveness, highlighting the need for careful dietary considerations.

Drug Metabolism and Genetic Variability

• Variability Sources: Include the presence of drug inducers and inhibitors from diet and medications that can alter metabolic pathways significantly.

• Genetic differences, particularly in enzyme activity due to polymorphisms, can explain why individuals respond variably to the same medication, emphasizing the role of pharmacogenomics in TDM.

Drugs Suitable for TDM

• Criteria:

  • Establishment of a proven relationship between drug levels and observable therapeutic effect.

  • Presence of a narrow therapeutic index where maintaining drug levels within an optimal range is critical due to the proximity of toxicity to efficacy.

Commonly Monitored Drugs

TDM Sample Collection Timing

• Steady State: Reached generally after 4-5 half-lives, indicating a stable drug concentration in the bloodstream and ensuring that dosing adjustments can be made based on consistent levels.

• Trough Level: Refers to the lowest concentration measured just before the next scheduled dose, crucial for ensuring drug levels remain within therapeutic range.

• Peak Level:

  • Oral Administration: Typically assessed 1 hour post-dose to monitor maximal drug concentrations.

  • IV Administration: Measured within 15-30 minutes post-dose for immediate action assessment.

Methods of TDM Measurement

• Types of Measurements: Routine measurements can be classified into total vs. free drug levels to ascertain active concentrations affecting therapeutic efficacy.

• Techniques: Common methods include immunoassays and advanced chromatography-mass spectrometry, considering factors such as turnaround time, associated costs, and potential interferences in measurement.

Adverse Drug Reactions (ADRs)

• Defined as injuries that result from medication use, which may adversely impact both physical and mental health, underscoring the importance of careful monitoring in drug administration.

• Consequences: ADRs result in increased morbidity and mortality, extended hospital stays, and heightened healthcare costs, demonstrating the critical need for monitoring and managing drug therapy.

Pharmacogenetics

• Focuses on understanding genetic factors that contribute to variations in drug responses among individuals, thereby facilitating more personalized approaches to medication.

• Goal: To enable adjustments in drug dosage or selection of alternative therapies to enhance both safety and efficacy in treatment plans, reflecting the trend towards precision medicine.

Case Study: Thiopurines

• Includes: Thioguanine, Mercaptopurine, Azathioprine—drugs commonly used in the management of autoimmune diseases and malignancies.

• Uses: Effective in organ transplantation, treatment of inflammatory disorders, and management of lymphoid malignancies, requiring careful monitoring for toxicity.

• Toxicity: Notable side effects include bone marrow suppression, hepatotoxicity, and pancreatitis, emphasizing the necessity for vigilant TDM.

Azathioprine Metabolism

• Metabolized by Thiopurine methyltransferase (TPMT), where variations in enzymatic activity due to genetic polymorphisms necessitate adjustments in dosing protocols to avoid toxicity.

Optimizing Thiopurine Therapy

• Preemptive Testing: TPMT genotyping or phenotyping advised prior to initiating thiopurine therapy.

• TDM: Monitoring of thiopurine metabolite levels (6-TG, 6-MMP) in erythrocytes is crucial for adequate dosing and to mitigate potential toxicities effectively.

Conclusion

• Various individual factors can cause significant inter-individual variations in drug concentrations, which necessitates vigilant therapeutic drug monitoring.

• TDM is essential for certain drugs to ensure optimal therapeutic outcomes, emphasizing the importance of correct timing in sample collection and dose adjustments based on monitoring results.

• Combining TDM with pharmacogenetic testing is becoming increasingly vital, enhancing personalized treatment strategies and improving patient safety in drug therapies.